Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder

NEW HAVEN, Conn., Dec. 21, 2017 -- (Healthcare Sales & Marketing Network) -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neur... Biopharmaceuticals, Neurology Biohaven Pharmaceutical, trigriluzole, obsessive-compulsive disorder
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news